Amneal Pharmaceuticals, INC Schedule 13D activist filings

Tushar Patel reports increased beneficial ownership of Amneal Pharmaceuticals Class A Common Stock following the company's acquisition of Kashiv BioSciences.

Chirag Patel has increased his beneficial ownership in Amneal Pharmaceuticals, Inc. to 8.4% following the company's acquisition of Kashiv BioSciences.

Chintu Patel's Schedule 13D filing details his increased beneficial ownership of Amneal Pharmaceuticals Class A Common Stock following the company's acquisition of Kashiv BioSciences.

Dipan Patel's trusts sold nearly 7 million shares of Amneal Pharmaceuticals Class A Common Stock, reducing beneficial ownership to 5.4%.

Chintu Patel, a significant shareholder of Amneal Pharmaceuticals, Inc., has pledged over 13.2 million Class A Common Stock shares as collateral for a margin loan agreement with Citibank, N.A.

A trust controlled by Amneal Pharmaceuticals' significant shareholder, Dipan Patel, has pledged 3,050,000 Class A Common Stock shares as collateral for a $10 million loan from Enterprise Bank & Trust.

Chirag Patel and related trusts increased pledged Amneal Pharmaceuticals Class A Common Stock to 19 million shares and extended the maturity of a margin loan agreement with UBS to April 29, 2028.

Tushar Patel, a significant beneficial owner of Amneal Pharmaceuticals, Inc., sold 5 million shares of Class A Common Stock for $8.35 per share to obtain liquidity.

Dipan Patel, through controlled trusts, sold over 3 million shares of Amneal Pharmaceuticals stock between July and November 2024, reducing his beneficial ownership to 7.7%.